ZyVersa Therapeutics (ZVSA) 10-Q 15 May 24 2024 Q1 Quarterly report Financial data

Cover

Cover - shares	3 Months Ended
	Mar. 31, 2024	May 10, 2024
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Mar. 31, 2024
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2024
Current Fiscal Year End Date	--12-31
Entity File Number	001-41184
Entity Registrant Name	ZYVERSA THERAPEUTICS, INC.
Entity Central Index Key	0001859007
Entity Tax Identification Number	86-2685744
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	2200 N. Commerce Parkway
Entity Address, Address Line Two	Suite 208
Entity Address, City or Town	Weston
Entity Address, State or Province	FL
Entity Address, Postal Zip Code	33326
City Area Code	(754)
Local Phone Number	231-1688
Title of 12(b) Security	Common Stock, $0.0001 par value per share
Trading Symbol	ZVSA
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Elected Not To Use the Extended Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		834,896

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Current Assets:
Cash	$ 2,033,576	$ 3,137,674
Prepaid expenses and other current assets	866,476	215,459
Total Current Assets	2,900,052	3,353,133
Equipment, net	4,333	6,933
In-process research and development	18,647,903	18,647,903
Vendor deposit	98,476	98,476
Operating lease right-of-use asset		7,839
Total Assets	21,650,764	22,114,284
Current Liabilities:
Accounts payable	8,127,746	8,431,583
Accrued expenses and other current liabilities	1,454,970	1,754,533
Operating lease liability		8,656
Total Current Liabilities	9,582,716	10,194,772
Deferred tax liability	844,914	844,914
Total Liabilities	10,427,630	11,039,686
Commitments and contingencies (Note 6)
Stockholders’ Equity:
Common stock, $0.0001 par value, 250,000,000 shares authorized; 834,903 and 405,212 shares issued as of March 31, 2024 and December 31, 2023, respectively, and 834,896 and 405,206 shares outstanding as of March 31, 2024 and December 31, 2023, respectively	83	40
Additional paid-in-capital	117,276,079	114,300,849
Accumulated deficit	(106,045,861)	(103,219,124)
Treasury stock, at cost, 7 shares at March 31, 2024 and December 31, 2023, respectively	(7,168)	(7,168)
Total Stockholders’ Equity	11,223,134	11,074,598
Total Liabilities and Stockholders’ Equity	21,650,764	22,114,284
Series A Preferred Stock [Member]
Stockholders’ Equity:
Preferred stock, value
Series B Preferred Stock [Member]
Stockholders’ Equity:
Preferred stock, value	$ 1	$ 1

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2024	Dec. 31, 2023
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	1,000,000	1,000,000
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	250,000,000	250,000,000
Common stock, shares issued	834,903	405,212
Common stock, shares outstanding	834,896	405,206
Treasury stock shares	7	7
Series A Preferred Stock [Member]
Preferred stock, shares authorized	8,635	8,635
Preferred stock, shares issued	50	50
Preferred stock, shares outstanding	50	50
Series B Preferred Stock [Member]
Preferred stock, shares authorized	5,062	5,062
Preferred stock, shares issued	5,062	5,062
Preferred stock, shares outstanding	5,062	5,062

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating Expenses:
Research and development	$ 512,937	$ 1,055,943
General and administrative	2,313,699	3,536,136
Total Operating Expenses	2,826,636	4,592,079
Loss From Operations	(2,826,636)	(4,592,079)
Other (Income) Expense:
Interest (income) expense	101	(1,078)
Pre-Tax Net Loss	(2,826,737)	(4,591,001)
Income tax benefit		1,047,051
Net Loss	$ (2,826,737)	$ (3,543,950)
Net Loss Per Share - Basic	$ (4.53)	$ (135.88)
Net Loss Per Share - Diluted	$ (4.53)	$ (135.88)
Weighted Average Number of Common Shares Outstanding - Basic	623,600	26,081
Weighted Average Number of Common Shares Outstanding - Diluted	623,600	26,081

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) - USD ($)	Preferred Stock [Member] Series A Preferred Stock [Member]	Preferred Stock [Member] Series B Preferred Stock [Member]	Common Stock [Member]	Treasury Stock, Common [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance - December 31, 2023 at Dec. 31, 2022	$ 1	$ 1	$ 902		$ 104,583,271	$ (4,921,178)	$ 99,662,997
Balance, shares at Dec. 31, 2022	8,635	5,062	25,760
Issuance of common stock pursuant to vendor agreements			$ 13		395,187		395,200
Issuance of common stock pursuant to vendor agreements, shares			371
Stock-based compensation					287,461		287,461
Net loss						(3,543,950)	(3,543,950)
Balance - March 31, 2024 at Mar. 31, 2023	$ 1	$ 1	$ 922		105,562,569	(8,465,128)	97,098,365
Balance, shares at Mar. 31, 2023	8,635	5,062	26,320
Balance - December 31, 2023 at Dec. 31, 2023		$ 1	$ 40	$ (7,168)	114,300,849	(103,219,124)	11,074,598
Balance, shares at Dec. 31, 2023	50	5,062	405,212	(7)
Exercise of warrants			$ 21		2,672,479		2,672,500
Exercise of warrants, shares			213,800
Exercise of pre-funded warrants			$ 13		(13)
Exercise of pre-funded warrants, shares			131,481
Issuance of common stock pursuant to vendor agreements			$ 1		79,199		79,200
Issuance of common stock pursuant to vendor agreements, shares			9,000
Round up share adjustment due to reverse split			$ 8		(8)
Stock-based compensation					223,573		223,573
Net loss						(2,826,737)	(2,826,737)
Balance - March 31, 2024 at Mar. 31, 2024		$ 1	$ 83	$ (7,168)	$ 117,276,079	$ (106,045,861)	$ 11,223,134
Balance, shares at Mar. 31, 2024	50	5,062	834,903	(7)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Changes in Stockholders' Equity (Deficiency) (Unaudited) - USD ($)	Preferred Stock [Member] Series A Preferred Stock [Member]	Preferred Stock [Member] Series B Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance - December 31, 2023 at Dec. 31, 2022	$ 1	$ 1	$ 902	$ 104,583,271	$ (4,921,178)	$ 99,662,997
Balance, shares at Dec. 31, 2022	8,635	5,062	25,760
Reclassification of formerly redeemable common stock			$ 7	331,324		331,331
Reclassification of formerly redeemable common stock, shares			188
Issuance of common stock pursuant to vendor agreements			$ 13	395,187		395,200
Issuance of common stock pursuant to vendor agreements, shares			371
Registration costs associated with preferred stock issuance				(34,674)		(34,674)
Stock-based compensation				287,461		287,461
Net loss					(3,543,950)	(3,543,950)
Balance - March 31, 2024 at Mar. 31, 2023	$ 1	$ 1	$ 922	105,562,569	(8,465,128)	97,098,365
Balance, shares at Mar. 31, 2023	8,635	5,062	26,320
Balance - December 31, 2023 at Dec. 31, 2023		$ 1	$ 40	114,300,849	(103,219,124)	11,074,598
Balance, shares at Dec. 31, 2023	50	5,062	405,212
Issuance of common stock pursuant to vendor agreements			$ 1	79,199		79,200
Issuance of common stock pursuant to vendor agreements, shares			9,000
Stock-based compensation				223,573		223,573
Net loss					(2,826,737)	(2,826,737)
Balance - March 31, 2024 at Mar. 31, 2024		$ 1	$ 83	$ 117,276,079	$ (106,045,861)	$ 11,223,134
Balance, shares at Mar. 31, 2024	50	5,062	834,903

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Cash Flows From Operating Activities:
Net loss	$ (2,826,737)	$ (3,543,950)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation	223,573	287,461
Issuance of common stock pursuant to vendor agreements	79,200	395,200
Depreciation of fixed assets	2,600	2,600
Non-cash rent expense	7,839	22,047
Deferred tax benefit		(1,047,051)
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	(651,017)	(1,096,204)
Accounts payable	(303,837)	355,441
Operating lease liability	(8,656)	(24,249)
Accrued expenses and other current liabilities	(299,563)	59,253
Net Cash Used In Operating Activities	(3,776,598)	(4,589,452)
Cash Flows From Financing Activities:
Exercise of warrants	2,672,500
Registration and issuance costs associated with preferred stock issuance		(34,674)
Net Cash Provided By (Used In) Financing Activities	2,672,500	(34,674)
Net Decrease in Cash	(1,104,098)	(4,624,126)
Cash - Beginning of Period	3,137,674	5,902,199
Cash - End of Period	2,033,576	1,278,073
Supplemental Disclosures of Cash Flow Information:
Reclassification of formerly redeemable common stock		$ 331,331

Business Organization, Nature o

Business Organization, Nature of Operations and Basis of Presentation	3 Months Ended
	Mar. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Business Organization, Nature of Operations and Basis of Presentation	Note 1 – Business Organization, Nature of Operations and Basis of Presentation Organization and Operations ZyVersa is a clinical stage biopharmaceutical company leveraging proprietary technologies to develop first-in-class drugs for patients with chronic renal or inflammatory diseases with high unmet medical needs. The Company’s mission is to develop drugs that optimize health outcomes and improve patients’ quality of life. Basis of Presentation and Principles of Consolidation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information. Accordingly, they do not include all of the information and disclosures required by accounting principles generally accepted in the United States of America for annual financial statements. In the opinion of management, such statements include all adjustments (consisting only of normal recurring items) which are considered necessary for a fair presentation of the unaudited condensed consolidated financial statements of the Company as of March 31, 2024 and for the three months ended March 31, 2024 and 2023. The results of operations for the three months ended March 31, 2024 are not necessarily indicative of the operating results for the full year. It is suggested that these unaudited condensed consolidated financial statements be read in conjunction with the consolidated financial statements and notes thereto included in the Company’s annual report on Form 10-K for the year ended December 31, 2023, filed with the Securities and Exchange Commission (“SEC”) on March 25, 2024. On December 4, 2023, the Company effected a reverse stock split of its common stock at a ratio of 1-for-35 (the “2023 Reverse Split”). Upon the effectiveness of the 2023 Reverse Split, every 35 issued shares of common stock were reclassified and combined into one share of common stock. On April 25, 2024, the Company effected a reverse stock split of its common stock at a ratio of 1-for-10 (the “2024 Reverse Split”). Upon the effectiveness of the 2024 Reverse Split, every 10 issued shares of common stock were reclassified and combined into one share of common stock. Accordingly, all share and per share amounts for all periods presented in these financial statements and notes thereto have been adjusted retroactively, where applicable, to reflect the 2023 Reverse Split and the 2024 Reverse Split and adjustment of the conversion price or exercise price of each outstanding equity award, convertible security and warrant as if the transaction had occurred as of the beginning of the earliest period presented. See Note 8 – Subsequent Events – Reverse Stock Split. ZYVERSA THERAPEUTICS, INC. Notes to Condensed Consolidated Financial Statements

Going Concern and Management_s

Going Concern and Management’s Plans	3 Months Ended
	Mar. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Going Concern and Management’s Plans	Note 2 - Going Concern and Management’s Plans The accompanying condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of asset amounts or the classification of liabilities that might be necessary should the Company be unable to continue as a going concern. As of March 31, 2024, the Company had cash of approximately $ 2.0 6.7 2.8 3.8 106.0 The Company has not yet achieved profitability and expects to continue to incur cash outflows from operations. It is expected that its research and development and general and administrative expenses will continue to increase and, as a result, the Company will eventually need to generate significant product revenues to achieve profitability. Consequently, the Company will be required to raise additional funds through equity or debt financing. Management believes that the Company has access to capital resources and continues to evaluate additional financing opportunities; however, and there can be no assurance that it will be successful in securing additional capital or that the Company will be able to obtain funds on commercially acceptable terms, if at all. There is also no assurance that the amount of funds the Company might raise will enable the Company to complete its development initiatives or attain profitable operations. The aforementioned conditions raise substantial doubt about the Company’s ability to continue as a going concern for at least one year from the issuance date of these financial statements.

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2024
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 3 – Summary of Significant Accounting Policies Since the date the Company’s December 31, 2023 financial statements were issued in its 2023 Annual Report on Form 10-K, there have been no material changes to the Company’s significant accounting policies. Use of Estimates Preparation of financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the amounts reported in the financial statements and the amounts disclosed in the related notes to the financial statements. The Company bases its estimates and judgments on historical experience and on various other assumptions that it believes are reasonable under the circumstances. The amounts of assets and liabilities reported in the Company’s balance sheets and the amounts of expenses reported for each of the periods presented are affected by estimates and assumptions, which are used for, but not limited to, fair value calculations for equity securities, derivative liabilities, share based compensation and acquired intangible assets, as well as establishment of valuation allowances for deferred tax assets. Certain of the Company’s estimates could be affected by external conditions, including those unique to the Company and general economic conditions. It is reasonably possible that actual results could differ from those estimates. ZYVERSA THERAPEUTICS, INC. Notes to Condensed Consolidated Financial Statements Net Loss Per Common Share Basic net loss per common share is computed by dividing net loss by the weighted average number of vested common shares outstanding during the period. Diluted net income per common share is computed by dividing net income by the weighted average number of common and dilutive common-equivalent shares outstanding during each period. The following table sets forth the outstanding potentially dilutive securities that have been excluded from the calculation of diluted net loss per share because to do so would be anti-dilutive: Schedule of Anti-dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share 2024 2023 For the Three Months Ended March 31, 2024 2023 Warrants [1] 689,520 24,653 (2) Options 10,243 6,086 Series A Convertible Preferred Stock 72 2,467 (3) Series B Convertible Preferred Stock 2,067 1,446 (4) Total potentially dilutive shares 701,902 34,653 [1] As part of the InflamaCORE, LLC license agreement, warrants to purchase 341 shares of common stock are to be issued upon the satisfaction of certain milestones and, accordingly, are not included in the amount currently reported. See Note 6 - Commitments and Contingencies - License Agreements for details. [2] Does not include an additional 9,869 [3] Does not include an additional 9,689 [4] Does not include an additional 620 Segment Reporting The Company operates and manages its business as one reportable and operating segment. All assets and operations are in the U.S. The Company’s Chief Executive Officer, who is the chief operating decision maker, reviews financial information on an aggregate basis for purposes of allocating resources and evaluating financial performance. Reclassifications Certain prior period balances have been reclassified from security deposits to vendor deposits on the condensed consolidated balance sheet in order to conform to the current year presentation. These reclassifications had no effect on previously reported results of operations or loss per share. Recently Issued Accounting Pronouncements In November 2023, the FASB issued ASU 2023-07 “Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures.” These amendments require a public entity to disclose significant segment expenses and other segment items on an annual and interim basis and to provide in interim periods all disclosures about a reportable segment’s profit or loss and assets that are currently required annually. Public entities with a single reporting segment are required to provide both the new disclosures and all of the existing disclosures required under ASC 280. The guidance is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. Since this new ASU addresses only disclosures, the Company does not expect the adoption of this ASU to have any material effects on its financial condition, results of operations or cash flows. The Company is currently evaluating any new disclosures that may be required upon adoption of ASU 2023-07. In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. The amendments in this update address investor requests for more transparency about income tax information through improvements to income tax disclosures primarily related to the rate reconciliation and income taxes paid information. This update also includes certain other amendments to improve the effectiveness of income tax disclosures. The amendments in ASU 2023-09 are effective for the Company for annual periods beginning after December 15, 2024, with early adoption permitted. Since this new ASU addresses only disclosures, the Company does not expect the adoption to have any material effects on its financial condition, results of operation or cash flows. The Company is currently evaluating any new disclosures that may be required upon adoption of ASU 2023-09. ZYVERSA THERAPEUTICS, INC. Notes to Condensed Consolidated Financial Statements

Accrued Expenses and Other Curr

Accrued Expenses and Other Current Liabilities	3 Months Ended
	Mar. 31, 2024
Payables and Accruals [Abstract]
Accrued Expenses and Other Current Liabilities	Note 4 – Accrued Expenses and Other Current Liabilities Accrued expenses and other current liabilities consisted of the following as of March 31, 2024 and December 31, 2023: Schedule of Accrued Expenses and Other Current Liabilities March 31, December 31, 2024 2023 L&F milestone payment liability $ - $ 500,000 Payroll accrual 668,803 668,803 Other accrued expenses 51,969 41,969 Bonus accrual 726,937 536,500 Registration delay liability [1] 7,261 7,261 Total accrued expenses and other current liabilities $ 1,454,970 $ 1,754,533 [1] See Note 7 – Stockholders’ Permanent and Temporary Equity for details of the registration delay liability.

Income Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2024
Income Tax Disclosure [Abstract]
Income Taxes	Note 5 – Income Taxes Income tax expense and the effective tax rate were as follows: Schedule of Income Taxes Expense Effective Tax Rate (in thousands) 2024 2023 For the Three Months Ended March 31, (in thousands) 2024 2023 Income tax benefit $ - $ 1,047,051 Effective tax rate 0.00 % 22.81 % The tax provisions for the three months ended March 31, 2024 and 2023 were computed using the estimated effective tax rates applicable to the taxable jurisdictions for the full year. The Company’s tax rate is subject to management’s quarterly review and revision, as necessary. The Company’s effective tax rate was 0.00 22.81

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2024
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 6 – Commitments and Contingencies Litigations, Claims and Assessments The Company may be involved in legal proceedings, claims and assessments arising in the ordinary course of business. The Company records contingent liabilities resulting from such claims, if any, when a loss is assessed to be probable and the amount of the loss is reasonably estimable. ZYVERSA THERAPEUTICS, INC. Notes to Condensed Consolidated Financial Statements License Agreements L&F Research LLC The Company entered into a License Agreement with L&F Research LLC (“L&F Research”) effective December 15, 2015, as amended (the “L&F License Agreement”) pursuant to which L&F granted the Company an exclusive royalty-bearing, worldwide, sublicensable license under the patent and intellectual property rights and know-how specific to and for the development and commercialization of VAR 200, for the treatment, inhibition or prevention of kidney disease in humans and symptoms thereof, including focal segmental glomerulosclerosis. On February 28, 2023, the Company and L&F executed an Amendment and Restatement Agreement that waived L&F’s right to terminate the L&F License Agreement or any other remedies, for non-payment of the First Milestone Payment, until (a) March 31, 2023 as to $1,000,000 of such milestone payments (“Waiver A”) and (b) January 31, 2024 as to $500,000 milestone payments (“Waiver B”). 351,579 648,421 500,000 January 31, 2024 30,000,000 On March 29, 2023, the Company paid the $ 648,421 188 331,331 On January 30, 2024, the Company paid $ 500,000 Operating Leases On January 18, 2019, the Predecessor entered into a lease agreement for approximately 3,500 89,000 497,000 112,064 The Company recognized right-of-use asset amortization of $ 7,839 22,047 ZYVERSA THERAPEUTICS, INC. Notes to Condensed Consolidated Financial Statements A summary of the Company’s right-of-use assets and liabilities is as follows: Schedule of Right of Use Assets and Liabilities 2024 2023 For the Three Months Ended March 31, 2024 2023 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows used in operating activities $ 8,656 $ 24,249 Right-of-use assets obtained in exchange for lease obligations Operating leases $ - $ - Weighted Average Remaining Lease Term Operating leases - 0.84 Weighted Average Discount Rate Operating leases - 6.5 %

Stockholders_ Permanent and Tem

Stockholders’ Permanent and Temporary Equity	3 Months Ended
	Mar. 31, 2024
Equity [Abstract]
Stockholders’ Permanent and Temporary Equity	Note 7 – Stockholders’ Permanent and Temporary Equity Common Stock During the three months ended March 31, 2024, the Company entered into a marketing agreement with a vendor in which the Company issued an aggregate of 9,000 79,200 Temporary Equity See Note 6 – Commitments and Contingencies for discussion of the movement of temporary equity to permanent equity on March 29, 2023. Stock-Based Compensation For the three months ended March 31, 2024 the Company recorded stock-based compensation expense of $ 223,573 15,447 208,126 287,461 49,455 238,006 803,890 1.6 ZYVERSA THERAPEUTICS, INC. Notes to Condensed Consolidated Financial Statements Stock Options The grant date fair value of stock options granted during the three months ended March 31, 2024 and 2023 was determined using the Black Scholes method, with the following assumptions used: Schedule of Stock Options Granted For the Three Months Ended March 31, 2024 2023 Fair value of common stock on date of grant N/A $ 2.11 2.23 Risk free interest rate N/A 3.53 4.27 Expected term (years) N/A 6.00 Expected volatility N/A 120 122 Expected dividends N/A 0.00 A summary of the option activity for the three months ended March 31, 2024 is presented below: Schedule of Stock Option Activity Weighted Weighted Average Average Remaining Aggregate Number of Exercise Life Intrinsic Options Price In Years Value Outstanding, January 1, 2024 10,243 $ 2,218.51 Granted - - Exercised - - Forfeited - - Outstanding, March 31, 2024 10,243 $ 2,218.51 6.1 $ - Exercisable, March 31, 2024 6,150 $ 3,438.48 5.0 $ - The following table presents information related to stock options as of March 31, 2024: Schedule of Information Related to Stock Options Options Outstanding Options Exercisable Weighted Outstanding Average Exercisable Exercise Number of Remaining Life Number of Price Options In Years Options $ 152.50 4,157 9.1 429 $ 738.50 286 8.8 95 $ 791.00 38 8.9 12 $ 1,760.50 1,910 1.8 1,910 $ 3,965.50 37 8.2 37 $ 4,053.00 2,095 5.0 2,095 $ 5,726.00 1,720 7.2 1,572 10,243 5.0 6,150 ZYVERSA THERAPEUTICS, INC. Notes to Condensed Consolidated Financial Statements Stock Warrants Between February 26, 2024 and March 6, 2024, investors in the December 2023 Offering exercised warrants to purchase 213,800 12.50 2,672,500 Between January 17 and February 23, 2024, a December 2023 Offering investor exercised pre-funded warrants to purchase 131,500 131,481 0.001 A summary of the warrant activity for the three months ended March 31, 2024, is presented below: Summary of Warrant Activity Weighted Weighted Average Average Remaining Aggregate Number of Exercise Life Intrinsic Warrants Price In Years Value Outstanding, January 1, 2024 [1] 903,320 $ 123.44 Issued - - Exercised [2] (213,800 ) 12.50 Outstanding, March 31, 2024 689,520 $ 157.92 3.67 $ - Exercisable, March 31, 2024 689,320 $ 157.46 3.67 $ - [1] Warrants outstanding exclude 131,500 0.001 [2] Warrants exercised exclude 131,500 0.001 The following table presents information related to stock warrants as of March 31, 2024: Schedule of Information Related to Stock Warrants Warrants Outstanding Warrants Exercisable Outstanding Weighted Average Exercisable Exercise Number of Remaining Life Number of Price Warrants In Years Warrants $ 12.50 586,200 3.58 586,200 $ 47.50 20,347 4.95 20,347 $ 57.75 19,965 4.27 19,965 $ 350.00 27,551 4.07 27,551 $ 700.00 13,944 3.70 13,944 $ 1,760.50 300 0.27 100 $ 2,415.00 3,651 3.70 3,651 $ 4,025.00 17,335 3.70 17,335 $ 4,053.00 227 0.05 227 689,520 3.67 689,320 ZYVERSA THERAPEUTICS, INC. Notes to Condensed Consolidated Financial Statements Effectiveness Failure In connection with the Business Combination, the Company conducted the Successor Series A Preferred Stock Financing. On or about February 20, 2023, the Company failed to have the SEC declare a registration statement effective (the “Effectiveness Failure”) which covered the Successor Series A Preferred Stock registrable securities within the time period prescribed by the Securities Purchase Agreement (the “SPA”). The SPA entitles the investors to receive registration delay payments (“Registration Delay Payments”) equal to 1.5 2.0 7,261

Subsequent Events

Subsequent Events	3 Months Ended
	Mar. 31, 2024
Subsequent Events [Abstract]
Subsequent Events	Note 8 – Subsequent Events 2024 Reverse Stock Split On April 25, 2024, the Company effected a reverse stock split of its common stock at a ratio of 1-for-10 (the “2024 Reverse Split”). Upon the effectiveness of the 2024 Reverse Split, every 10 issued shares of common stock were reclassified and combined into one share of common stock.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2024
Accounting Policies [Abstract]
Use of Estimates	Use of Estimates Preparation of financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the amounts reported in the financial statements and the amounts disclosed in the related notes to the financial statements. The Company bases its estimates and judgments on historical experience and on various other assumptions that it believes are reasonable under the circumstances. The amounts of assets and liabilities reported in the Company’s balance sheets and the amounts of expenses reported for each of the periods presented are affected by estimates and assumptions, which are used for, but not limited to, fair value calculations for equity securities, derivative liabilities, share based compensation and acquired intangible assets, as well as establishment of valuation allowances for deferred tax assets. Certain of the Company’s estimates could be affected by external conditions, including those unique to the Company and general economic conditions. It is reasonably possible that actual results could differ from those estimates. ZYVERSA THERAPEUTICS, INC. Notes to Condensed Consolidated Financial Statements
Net Loss Per Common Share	Net Loss Per Common Share Basic net loss per common share is computed by dividing net loss by the weighted average number of vested common shares outstanding during the period. Diluted net income per common share is computed by dividing net income by the weighted average number of common and dilutive common-equivalent shares outstanding during each period. The following table sets forth the outstanding potentially dilutive securities that have been excluded from the calculation of diluted net loss per share because to do so would be anti-dilutive: Schedule of Anti-dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share 2024 2023 For the Three Months Ended March 31, 2024 2023 Warrants [1] 689,520 24,653 (2) Options 10,243 6,086 Series A Convertible Preferred Stock 72 2,467 (3) Series B Convertible Preferred Stock 2,067 1,446 (4) Total potentially dilutive shares 701,902 34,653 [1] As part of the InflamaCORE, LLC license agreement, warrants to purchase 341 shares of common stock are to be issued upon the satisfaction of certain milestones and, accordingly, are not included in the amount currently reported. See Note 6 - Commitments and Contingencies - License Agreements for details. [2] Does not include an additional 9,869 [3] Does not include an additional 9,689 [4] Does not include an additional 620
Segment Reporting	Segment Reporting The Company operates and manages its business as one reportable and operating segment. All assets and operations are in the U.S. The Company’s Chief Executive Officer, who is the chief operating decision maker, reviews financial information on an aggregate basis for purposes of allocating resources and evaluating financial performance.
Reclassifications	Reclassifications Certain prior period balances have been reclassified from security deposits to vendor deposits on the condensed consolidated balance sheet in order to conform to the current year presentation. These reclassifications had no effect on previously reported results of operations or loss per share.
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements In November 2023, the FASB issued ASU 2023-07 “Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures.” These amendments require a public entity to disclose significant segment expenses and other segment items on an annual and interim basis and to provide in interim periods all disclosures about a reportable segment’s profit or loss and assets that are currently required annually. Public entities with a single reporting segment are required to provide both the new disclosures and all of the existing disclosures required under ASC 280. The guidance is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. Since this new ASU addresses only disclosures, the Company does not expect the adoption of this ASU to have any material effects on its financial condition, results of operations or cash flows. The Company is currently evaluating any new disclosures that may be required upon adoption of ASU 2023-07. In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. The amendments in this update address investor requests for more transparency about income tax information through improvements to income tax disclosures primarily related to the rate reconciliation and income taxes paid information. This update also includes certain other amendments to improve the effectiveness of income tax disclosures. The amendments in ASU 2023-09 are effective for the Company for annual periods beginning after December 15, 2024, with early adoption permitted. Since this new ASU addresses only disclosures, the Company does not expect the adoption to have any material effects on its financial condition, results of operation or cash flows. The Company is currently evaluating any new disclosures that may be required upon adoption of ASU 2023-09.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2024
Accounting Policies [Abstract]
Schedule of Anti-dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share	The following table sets forth the outstanding potentially dilutive securities that have been excluded from the calculation of diluted net loss per share because to do so would be anti-dilutive: Schedule of Anti-dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share 2024 2023 For the Three Months Ended March 31, 2024 2023 Warrants [1] 689,520 24,653 (2) Options 10,243 6,086 Series A Convertible Preferred Stock 72 2,467 (3) Series B Convertible Preferred Stock 2,067 1,446 (4) Total potentially dilutive shares 701,902 34,653 [1] As part of the InflamaCORE, LLC license agreement, warrants to purchase 341 shares of common stock are to be issued upon the satisfaction of certain milestones and, accordingly, are not included in the amount currently reported. See Note 6 - Commitments and Contingencies - License Agreements for details. [2] Does not include an additional 9,869 [3] Does not include an additional 9,689 [4] Does not include an additional 620

Accrued Expenses and Other Cu_2

Accrued Expenses and Other Current Liabilities (Tables)	3 Months Ended
	Mar. 31, 2024
Payables and Accruals [Abstract]
Schedule of Accrued Expenses and Other Current Liabilities	Accrued expenses and other current liabilities consisted of the following as of March 31, 2024 and December 31, 2023: Schedule of Accrued Expenses and Other Current Liabilities March 31, December 31, 2024 2023 L&F milestone payment liability $ - $ 500,000 Payroll accrual 668,803 668,803 Other accrued expenses 51,969 41,969 Bonus accrual 726,937 536,500 Registration delay liability [1] 7,261 7,261 Total accrued expenses and other current liabilities $ 1,454,970 $ 1,754,533 [1] See Note 7 – Stockholders’ Permanent and Temporary Equity for details of the registration delay liability.

Income Taxes (Tables)

Income Taxes (Tables)	3 Months Ended
	Mar. 31, 2024
Income Tax Disclosure [Abstract]
Schedule of Income Taxes Expense Effective Tax Rate	Income tax expense and the effective tax rate were as follows: Schedule of Income Taxes Expense Effective Tax Rate (in thousands) 2024 2023 For the Three Months Ended March 31, (in thousands) 2024 2023 Income tax benefit $ - $ 1,047,051 Effective tax rate 0.00 % 22.81 %

Commitments and Contingencies (

Commitments and Contingencies (Tables)	3 Months Ended
	Mar. 31, 2024
Commitments and Contingencies Disclosure [Abstract]
Schedule of Right of Use Assets and Liabilities	A summary of the Company’s right-of-use assets and liabilities is as follows: Schedule of Right of Use Assets and Liabilities 2024 2023 For the Three Months Ended March 31, 2024 2023 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows used in operating activities $ 8,656 $ 24,249 Right-of-use assets obtained in exchange for lease obligations Operating leases $ - $ - Weighted Average Remaining Lease Term Operating leases - 0.84 Weighted Average Discount Rate Operating leases - 6.5 %

Stockholders_ Permanent and T_2

Stockholders’ Permanent and Temporary Equity (Tables)	3 Months Ended
	Mar. 31, 2024
Equity [Abstract]
Schedule of Stock Options Granted	The grant date fair value of stock options granted during the three months ended March 31, 2024 and 2023 was determined using the Black Scholes method, with the following assumptions used: Schedule of Stock Options Granted For the Three Months Ended March 31, 2024 2023 Fair value of common stock on date of grant N/A $ 2.11 2.23 Risk free interest rate N/A 3.53 4.27 Expected term (years) N/A 6.00 Expected volatility N/A 120 122 Expected dividends N/A 0.00
Schedule of Stock Option Activity	A summary of the option activity for the three months ended March 31, 2024 is presented below: Schedule of Stock Option Activity Weighted Weighted Average Average Remaining Aggregate Number of Exercise Life Intrinsic Options Price In Years Value Outstanding, January 1, 2024 10,243 $ 2,218.51 Granted - - Exercised - - Forfeited - - Outstanding, March 31, 2024 10,243 $ 2,218.51 6.1 $ - Exercisable, March 31, 2024 6,150 $ 3,438.48 5.0 $ -
Schedule of Information Related to Stock Options	The following table presents information related to stock options as of March 31, 2024: Schedule of Information Related to Stock Options Options Outstanding Options Exercisable Weighted Outstanding Average Exercisable Exercise Number of Remaining Life Number of Price Options In Years Options $ 152.50 4,157 9.1 429 $ 738.50 286 8.8 95 $ 791.00 38 8.9 12 $ 1,760.50 1,910 1.8 1,910 $ 3,965.50 37 8.2 37 $ 4,053.00 2,095 5.0 2,095 $ 5,726.00 1,720 7.2 1,572 10,243 5.0 6,150
Summary of Warrant Activity	A summary of the warrant activity for the three months ended March 31, 2024, is presented below: Summary of Warrant Activity Weighted Weighted Average Average Remaining Aggregate Number of Exercise Life Intrinsic Warrants Price In Years Value Outstanding, January 1, 2024 [1] 903,320 $ 123.44 Issued - - Exercised [2] (213,800 ) 12.50 Outstanding, March 31, 2024 689,520 $ 157.92 3.67 $ - Exercisable, March 31, 2024 689,320 $ 157.46 3.67 $ - [1] Warrants outstanding exclude 131,500 0.001 [2] Warrants exercised exclude 131,500 0.001
Schedule of Information Related to Stock Warrants	The following table presents information related to stock warrants as of March 31, 2024: Schedule of Information Related to Stock Warrants Warrants Outstanding Warrants Exercisable Outstanding Weighted Average Exercisable Exercise Number of Remaining Life Number of Price Warrants In Years Warrants $ 12.50 586,200 3.58 586,200 $ 47.50 20,347 4.95 20,347 $ 57.75 19,965 4.27 19,965 $ 350.00 27,551 4.07 27,551 $ 700.00 13,944 3.70 13,944 $ 1,760.50 300 0.27 100 $ 2,415.00 3,651 3.70 3,651 $ 4,025.00 17,335 3.70 17,335 $ 4,053.00 227 0.05 227 689,520 3.67 689,320

Business Organization, Nature_2

Business Organization, Nature of Operations and Basis of Presentation (Details Narrative)	Apr. 25, 2024	Dec. 04, 2023
Subsequent Event [Line Items]
Reverse stock split		the Company effected a reverse stock split of its common stock at a ratio of 1-for-35 (the “2023 Reverse Split”). Upon the effectiveness of the 2023 Reverse Split, every 35 issued shares of common stock were reclassified and combined into one share of common stock.
Subsequent Event [Member]
Subsequent Event [Line Items]
Reverse stock split	the Company effected a reverse stock split of its common stock at a ratio of 1-for-10 (the “2024 Reverse Split”). Upon the effectiveness of the 2024 Reverse Split, every 10 issued shares of common stock were reclassified and combined into one share of common stock.

Going Concern and Management__2

Going Concern and Management’s Plans (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Cash	$ 2,033,576		$ 3,137,674
Working capital deficit	6,700,000
Net loss	2,826,737	$ 3,543,950
Net cash used In operating activities	(3,776,598)	$ (4,589,452)
Accumulated deficit	$ 106,045,861		$ 103,219,124

Schedule of Anti-dilutive Secur

Schedule of Anti-dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share (Details) - shares		3 Months Ended
		Mar. 31, 2024	Mar. 31, 2023
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares		701,902	34,653
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares	[1]	689,520	24,653	[2]
Share-Based Payment Arrangement, Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares		10,243	6,086
Series A Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares		72	2,467	[3]
Series B Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares		2,067	1,446	[4]
[1]As part of the InflamaCORE, LLC license agreement, warrants to purchase 341 shares of common stock are to be issued upon the satisfaction of certain milestones and, accordingly, are not included in the amount currently reported. See Note 6 - Commitments and Contingencies - License Agreements for details.[2]Does not include an additional 9,869 9,689 620

Schedule of Anti-dilutive Sec_2

Schedule of Anti-dilutive Securities Excluded From Calculation of Diluted Net Loss Per Share (Details) (Parenthetical)	3 Months Ended
	Mar. 31, 2024 shares
Series A Warrant [Member]
Shares available for conversion	9,869
Series A Convertible Preferred Stock [Member]
Shares available for conversion	9,689
Series B Convertible Preferred Stock [Member]
Shares available for conversion	620

Schedule of Accrued Expenses an

Schedule of Accrued Expenses and Other Current Liabilities (Details) - USD ($)		Mar. 31, 2024	Dec. 31, 2023
Payables and Accruals [Abstract]
L&F milestone payment liability			$ 500,000
Payroll accrual		668,803	668,803
Other accrued expenses		51,969	41,969
Bonus accrual		726,937	536,500
Registration delay liability	[1]	7,261	7,261
Total accrued expenses and other current liabilities		$ 1,454,970	$ 1,754,533
[1]See Note 7 – Stockholders’ Permanent and Temporary Equity for details of the registration delay liability.

Schedule of Income Taxes Expens

Schedule of Income Taxes Expense Effective Tax Rate (Details) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Tax Disclosure [Abstract]
Income tax benefit		$ 1,047,051
Effective tax rate	0%	22.81%

Income Taxes (Details Narrative

Income Taxes (Details Narrative)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Tax Disclosure [Abstract]
Effective tax rate	0%	22.81%

Schedule of Right of Use Assets

Schedule of Right of Use Assets and Liabilities (Details) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Commitments and Contingencies Disclosure [Abstract]
Operating cash flows used in operating activities	$ 8,656	$ 24,249
Operating leases
Weighted average remaining lease term		10 months 2 days
Weighted average discount rate		6.50%

Commitments and Contingencies_2

Commitments and Contingencies (Details Narrative)						3 Months Ended
	Jan. 30, 2024 USD ($)	Jan. 15, 2024 USD ($)	Mar. 29, 2023 USD ($) shares	Feb. 28, 2023 USD ($)	Jan. 18, 2019 USD ($) ft²	Mar. 31, 2024 USD ($)
Cash payment						$ 7,261
Operating lease rent expense						22,047
Lessee, Lease, Description [Line Items]
Operating lease asset amortization						$ 7,839
Lease Commitment [Member]
Operating lease rent expense		$ 112,064
Predecessor [Member]
Number of operating lease square feet | ft²					3,500
Lease cost					$ 89,000
Operating lease rent expense					$ 497,000
License Agreement [Member] | L&F Research LLC [Member]
Milestone payment description				the Company and L&F executed an Amendment and Restatement Agreement that waived L&F’s right to terminate the L&F License Agreement or any other remedies, for non-payment of the First Milestone Payment, until (a) March 31, 2023 as to $1,000,000 of such milestone payments (“Waiver A”) and (b) January 31, 2024 as to $500,000 milestone payments (“Waiver B”).
License Agreement [Member] | L&F Research LLC [Member] | Waiver A [Member]
Debt forgiveness				$ 351,579
Cash payment			$ 648,421	648,421
Reclassification shares of common stock | shares			188
Reclassification shares of common stock value classified as temporary to permanent equity			$ 331,331
License Agreement [Member] | L&F Research LLC [Member] | Waiver B [Member]
Cash payment	$ 500,000			$ 500,000
Maturity date				Jan. 31, 2024
Net proceeds from issuance of equity capital				$ 30,000,000

Schedule of Stock Options Grant

Schedule of Stock Options Granted (Details)	3 Months Ended
	Mar. 31, 2023 $ / shares
Expected term (years)	6 years
Expected dividends	0%
Minimum [Member]
Fair value of common stock on date of grant	$ 2.11
Risk free interest rate	3.53%
Expected volatility	120%
Maximum [Member]
Fair value of common stock on date of grant	$ 2.23
Risk free interest rate	4.27%
Expected volatility	122%

Schedule of Stock Option Activi

Schedule of Stock Option Activity (Details)	3 Months Ended
	Mar. 31, 2024 USD ($) $ / shares shares
Equity [Abstract]
Number of options, outstanding beginning balance | shares	10,243
Weighted average exercise price, beginning balance | $ / shares	$ 2,218.51
Number of options, granted | shares
Weighted average exercise price, granted | $ / shares
Number of options, exercised | shares
Weighted average exercise price, exercised | $ / shares
Number of options, forfeited | shares
Weighted average exercise price, forfeited | $ / shares
Number of options, outstanding ending balance | shares	10,243
Weighted average exercise price, ending balance | $ / shares	$ 2,218.51
Weighted average remaining life in years, outstanding	6 years 1 month 6 days
Aggregate intrinsic value, ending balance | $
Number of options, exercisable ending balance | shares	6,150
Weighted average exercise price, Exercisable | $ / shares	$ 3,438.48
Weighted average remaining life in years, exercisable	5 years
Aggregate intrinsic value, exercisable | $

Schedule of Information Related

Schedule of Information Related to Stock Options (Details)	3 Months Ended
	Mar. 31, 2024 $ / shares shares
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options outstanding, Number of options	10,243
Options exercisable, weighted average remaining life in life	5 years
Options exercisable, Number of options	6,150
Exercise Price One [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options outstanding, exercise price | $ / shares	$ 152.50
Options outstanding, Number of options	4,157
Options exercisable, weighted average remaining life in life	9 years 1 month 6 days
Options exercisable, Number of options	429
Exercise Price Two [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options outstanding, exercise price | $ / shares	$ 738.50
Options outstanding, Number of options	286
Options exercisable, weighted average remaining life in life	8 years 9 months 18 days
Options exercisable, Number of options	95
Exercise Price Three [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options outstanding, exercise price | $ / shares	$ 791
Options outstanding, Number of options	38
Options exercisable, weighted average remaining life in life	8 years 10 months 24 days
Options exercisable, Number of options	12
Exercise Price Four [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options outstanding, exercise price | $ / shares	$ 1,760.50
Options outstanding, Number of options	1,910
Options exercisable, weighted average remaining life in life	1 year 9 months 18 days
Options exercisable, Number of options	1,910
Exercise Price Five [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options outstanding, exercise price | $ / shares	$ 3,965.50
Options outstanding, Number of options	37
Options exercisable, weighted average remaining life in life	8 years 2 months 12 days
Options exercisable, Number of options	37
Exercise Price Six [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options outstanding, exercise price | $ / shares	$ 4,053
Options outstanding, Number of options	2,095
Options exercisable, weighted average remaining life in life	5 years
Options exercisable, Number of options	2,095
Exercise Price Seven [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options outstanding, exercise price | $ / shares	$ 5,726
Options outstanding, Number of options	1,720
Options exercisable, weighted average remaining life in life	7 years 2 months 12 days
Options exercisable, Number of options	1,572

Summary of Warrant Activity (De

Summary of Warrant Activity (Details)	3 Months Ended
	Mar. 31, 2024 USD ($) $ / shares shares
Equity [Abstract]
Number of warrants, outstanding beginning balance	903,320	[1]
Weighted average exercise price, beginning balance | $ / shares	$ 123.44	[1]
Number of warrants, granted
Number of warrants, exercised	(213,800)	[2]
Weighted average exercise price, exercised | $ / shares	$ 12.50	[2]
Number of warrants, outstanding ending balance	689,520
Weighted average exercise price, ending balance | $ / shares	$ 157.92
Weighted average remaining life in years, outstanding	3 years 8 months 1 day
Aggregate intrinsic value, ending balance | $
Number of warrants, exercisable ending balance	689,320
Weighted average exercise price, Exercisable | $ / shares	$ 157.46
Weighted average remaining life in years, exercisable	3 years 8 months 1 day
Aggregate intrinsic value, exercisable | $
[1]Warrants outstanding exclude 131,500 0.001 131,500 0.001

Summary of Warrant Activity (_2

Summary of Warrant Activity (Details) (Parenthetical)	3 Months Ended
	Mar. 31, 2024 $ / shares shares
Class of Warrant or Right [Line Items]
Number of warrants, outstanding	10,243
Number of warrants, exercised	213,800	[1]
December 2023 Pre-Funded Warrants [Member]
Class of Warrant or Right [Line Items]
Number of warrants, outstanding	131,500
Warrants exercise price | $ / shares	$ 0.001
Number of warrants, exercised	131,500
Exercise price | $ / shares	$ 0.001
[1]Warrants exercised exclude 131,500 0.001

Schedule of Information Relat_2

Schedule of Information Related to Stock Warrants (Details) - $ / shares	3 Months Ended
	Mar. 31, 2024	Dec. 31, 2023	[1]
WarrantsOutstandingAndExercisableLineItems [Line Items]
Number of warrants, outstanding	689,520	903,320
Number of warrants, exercisable	689,320
Warrant [Member]
WarrantsOutstandingAndExercisableLineItems [Line Items]
Number of warrants, outstanding	689,520
Warrant exercisable, weighted average remaining life in life	3 years 8 months 1 day
Number of warrants, exercisable	689,320
Exercise Price One [Member] | Warrant [Member]
WarrantsOutstandingAndExercisableLineItems [Line Items]
Weighted average exercise price, outstanding	$ 12.50
Number of warrants, outstanding	586,200
Warrant exercisable, weighted average remaining life in life	3 years 6 months 29 days
Number of warrants, exercisable	586,200
Exercise Price Two [Member] | Warrant [Member]
WarrantsOutstandingAndExercisableLineItems [Line Items]
Weighted average exercise price, outstanding	$ 47.50
Number of warrants, outstanding	20,347
Warrant exercisable, weighted average remaining life in life	4 years 11 months 12 days
Number of warrants, exercisable	20,347
Exercise Price Three [Member] | Warrant [Member]
WarrantsOutstandingAndExercisableLineItems [Line Items]
Weighted average exercise price, outstanding	$ 57.75
Number of warrants, outstanding	19,965
Warrant exercisable, weighted average remaining life in life	4 years 3 months 7 days
Number of warrants, exercisable	19,965
Exercise Price Four [Member] | Warrant [Member]
WarrantsOutstandingAndExercisableLineItems [Line Items]
Weighted average exercise price, outstanding	$ 350
Number of warrants, outstanding	27,551
Warrant exercisable, weighted average remaining life in life	4 years 25 days
Number of warrants, exercisable	27,551
Exercise Price Five [Member] | Warrant [Member]
WarrantsOutstandingAndExercisableLineItems [Line Items]
Weighted average exercise price, outstanding	$ 700
Number of warrants, outstanding	13,944
Warrant exercisable, weighted average remaining life in life	3 years 8 months 12 days
Number of warrants, exercisable	13,944
Exercise Price Six [Member] | Warrant [Member]
WarrantsOutstandingAndExercisableLineItems [Line Items]
Weighted average exercise price, outstanding	$ 1,760.50
Number of warrants, outstanding	300
Warrant exercisable, weighted average remaining life in life	3 months 7 days
Number of warrants, exercisable	100
Exercise Price Seven [Member] | Warrant [Member]
WarrantsOutstandingAndExercisableLineItems [Line Items]
Weighted average exercise price, outstanding	$ 2,415
Number of warrants, outstanding	3,651
Warrant exercisable, weighted average remaining life in life	3 years 8 months 12 days
Number of warrants, exercisable	3,651
Exercise Price Eight [Member] | Warrant [Member]
WarrantsOutstandingAndExercisableLineItems [Line Items]
Weighted average exercise price, outstanding	$ 4,025
Number of warrants, outstanding	17,335
Warrant exercisable, weighted average remaining life in life	3 years 8 months 12 days
Number of warrants, exercisable	17,335
Exercise Price Nine [Member] | Warrant [Member]
WarrantsOutstandingAndExercisableLineItems [Line Items]
Weighted average exercise price, outstanding	$ 4,053
Number of warrants, outstanding	227
Warrant exercisable, weighted average remaining life in life	18 days
Number of warrants, exercisable	227
[1]Warrants outstanding exclude 131,500 0.001

Stockholders_ Permanent and T_3

Stockholders’ Permanent and Temporary Equity (Details Narrative) - USD ($)		3 Months Ended
	Mar. 06, 2024	Mar. 31, 2024	Mar. 31, 2023	Feb. 23, 2024	Feb. 20, 2023
Subsidiary, Sale of Stock [Line Items]
Stock based compensation expense		$ 223,573	$ 287,461
Unrecognized stock-based compensation expense		$ 803,890
weighted average period		1 year 7 months 6 days
Gross proceeds pre-funded warrants		$ 2,672,500
Percentage of registration delay payments					1.50%
Debt Instrument, Interest Rate, Stated Percentage					2%
Delay payment		7,261
Pre Funded Warrants [Member] | Investor [Member]
Subsidiary, Sale of Stock [Line Items]
Warrants to purchase common shares				131,500
Warrant exercise price				$ 0.001
Warrants exercised on cashless basis				131,481
December 2023 Offering [Member]
Subsidiary, Sale of Stock [Line Items]
Warrants to purchase common shares	213,800
Warrant exercise price	$ 12.50
Gross proceeds pre-funded warrants	$ 2,672,500
Research and Development Expense [Member]
Subsidiary, Sale of Stock [Line Items]
Stock based compensation expense		15,447	49,455
General and Administrative Expense [Member]
Subsidiary, Sale of Stock [Line Items]
Stock based compensation expense		$ 208,126	$ 238,006
Marketing Agreements [Member]
Subsidiary, Sale of Stock [Line Items]
Shares issued for services		9,000
Prepaid expense fair value of shares		$ 79,200

Subsequent Events (Details Narr

Subsequent Events (Details Narrative)	Apr. 25, 2024	Dec. 04, 2023
Subsequent Event [Line Items]
Reverse stock split		the Company effected a reverse stock split of its common stock at a ratio of 1-for-35 (the “2023 Reverse Split”). Upon the effectiveness of the 2023 Reverse Split, every 35 issued shares of common stock were reclassified and combined into one share of common stock.
Subsequent Event [Member]
Subsequent Event [Line Items]
Reverse stock split	the Company effected a reverse stock split of its common stock at a ratio of 1-for-10 (the “2024 Reverse Split”). Upon the effectiveness of the 2024 Reverse Split, every 10 issued shares of common stock were reclassified and combined into one share of common stock.